Yahoo · Sep 3, 2026
Cyberattack & Weak 2026 Outlook Weigh on BSX: Is the Stock a Sell?
Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.
AB
NASDAQ · ABT
Abbott Laboratories
Healthcare · Medical - Devices
$108.79
Up+$0.64 (+0.58%)
Updated Sep 4, 2026, 4:46 PM
SID Score
7.3/10
Composite research score
Smart Money
51/100
Neutral
- Market cap
- 202.45B
- P/E ratio
- 31.15
- Dividend yield
- 2.17%
- 52-week range
- $81.97 – $129.64
- Volume
- 5.3M
- Avg. volume
- 8.88M
Price performance
ABT price history
1M range · 21 trading sessions · Daily adjusted prices
ABT closed at $108.79 after 21 trading sessions, up 0.77% for the selected period.
- Last close
- $108.79
- Period change
- +0.77%
- Period low
- $107.81
- Period high
- $116.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 3, 2026 | $110.91 | $112.00 | $108.04 | $108.79 | 5.3M |
| Sep 2, 2026 | $109.32 | $112.20 | $109.00 | $110.47 | 8.46M |
| Sep 1, 2026 | $112.25 | $113.91 | $108.68 | $108.93 | 7.23M |
| Aug 31, 2026 | $111.54 | $111.64 | $109.54 | $110.36 | 10.69M |
| Aug 28, 2026 | $111.60 | $112.75 | $111.11 | $112.47 | 7.55M |
| Aug 27, 2026 | $112.75 | $113.45 | $111.29 | $111.59 | 8.36M |
| Aug 26, 2026 | $115.40 | $116.715 | $114.005 | $114.10 | 6.96M |
| Aug 25, 2026 | $115.83 | $116.61 | $115.035 | $116.13 | 7.5M |
| Aug 24, 2026 | $116.28 | $117.34 | $115.82 | $116.67 | 5.92M |
| Aug 21, 2026 | $114.02 | $116.66 | $113.4501 | $116.64 | 9.93M |
| Aug 20, 2026 | $114.00 | $115.23 | $113.99 | $114.14 | 5.79M |
| Aug 19, 2026 | $113.23 | $115.67 | $112.91 | $114.43 | 7.4M |
| Aug 18, 2026 | $112.45 | $113.63 | $111.745 | $112.68 | 9.78M |
| Aug 17, 2026 | $110.04 | $111.41 | $109.35 | $110.37 | 11.46M |
| Aug 14, 2026 | $111.49 | $111.97 | $110.79 | $111.25 | 5.58M |
| Aug 13, 2026 | $112.47 | $112.47 | $110.46 | $111.27 | 5.52M |
| Aug 12, 2026 | $108.05 | $111.28 | $107.50 | $110.91 | 6.61M |
| Aug 11, 2026 | $108.62 | $110.185 | $107.921 | $109.72 | 6.74M |
| Aug 10, 2026 | $107.41 | $109.09 | $107.36 | $108.62 | 5.6M |
| Aug 7, 2026 | $107.03 | $107.97 | $106.01 | $107.81 | 6.61M |
| Aug 6, 2026 | $107.185 | $107.99 | $105.56 | $107.96 | 9.8M |
Latest ABT news
The latest Smart Investors Daily articles mentioning ABT.
Stock researchCompany · Overview
ABT research
Overview
Company profile and research snapshot.
Company profile
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $151.40
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
| Jul 28, 2026 | UBS | Buy | — |
| Jul 17, 2026 | TD Cowen | Buy | — |
| Jul 17, 2026 | RBC Capital | Outperform | — |
News briefing
Generated Sep 4, 2026, 3:00 PM
Why Is ABT Up Today? Modest Gains Amid Mixed Healthcare Sector Signals
Abbott Laboratories edged up 0.43% today in a relatively quiet trading session, with the broader healthcare sector showing mixed momentum. While ABT itself generated no major breaking news, the company appears to be benefiting from a resilient market position as competitors face varied challenges and opportunities.
Bottom line: ABT's modest gain reflects a stock holding its ground amid mixed sector dynamics—neither benefiting from major catalysts nor facing direct headwinds from recent news. Investors should monitor the company's execution on pipeline programs and competitive positioning relative to strong performers like Medtronic, while remaining cognizant of sector-wide risks like cybersecurity threats and regulatory pressures.
Yahoo · Sep 2, 2026
Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Abbott (ABT) settling at $110.47, representing a +1.41% change from its previous close.
Yahoo · Sep 2, 2026
Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis® Pan-Cancer Strategy
SOPHIA ANTIPOLIS, France, September 02, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), developer of eyonis®, a suite of AI-powered Software as Medical Devices (SaMD) for the early detection and diagnosis of cancers, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced that its Board of Directors has formed a Strategic Review Committee (the "SRC")
Yahoo · Sep 2, 2026
3 Reasons to Sell PACB and 1 Stock to Buy Instead
Shareholders of PacBio would probably like to forget the past six months even happened. The stock dropped 20.5% and now trades at $1.29. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
AI research layers
Interpretive context generated from the platform’s current data sources.
Abbott Laboratories Stock Performance
Abbott Laboratories shares closed at $108.80, reflecting a modest daily gain of 0.47% per SID market data. The stock has demonstrated strong near-term momentum, rising 4.75% over the past month and surging 26.99% over the trailing three-month period. However, on a twelve-month basis, ABT remains down 11.68%, indicating the recent rally represents a recovery from a prolonged drawdown rather than a sustained uptrend. Technically, the stock trades above both its 50-day moving average of $103.71 and its 200-day moving average of $103.76, according to Massive/Polygon data, suggesting a bullish crossover positioning. The 14-day RSI reads 47.9, placing ABT in neutral territory without overbought or oversold conditions. Average daily volume stands at approximately 8.88 million shares. The stock's beta of 0.751 confirms its lower-volatility profile relative to the broader market, consistent with its defensive healthcare sector classification.
Abbott Laboratories Valuation Analysis
Abbott Laboratories carries a market capitalization of approximately $202.5 billion, positioning it among the largest healthcare companies globally, per SID market data. The stock trades at a price-to-earnings ratio of 31.15, which represents a premium to the broader S&P 500 healthcare sector average. The price-to-book ratio stands at 3.90, reflecting significant intangible asset value embedded in Abbott's diversified medical device and diagnostics portfolio. Notably, the PEG ratio registers at -0.58, according to SEC filings, indicating that trailing growth metrics currently present a negative or contracting earnings growth trajectory, which complicates traditional growth-adjusted valuation assessments. Abbott offers a dividend yield of 2.06%, providing income-oriented investors with steady cash returns. The company is a Dividend Aristocrat with decades of consecutive dividend increases. These valuation metrics collectively suggest ABT commands a premium multiple, supported by its diversified revenue streams across diagnostics, medical devices, nutrition, and established pharmaceuticals.
Smart Money Activity for ABT
Abbott Laboratories registers a composite smart money score of 51 out of 100, reflecting a neutral overall signal per SID market data. Institutional positioning is the standout metric, scoring a perfect 25 out of 25, indicating robust accumulation and strong conviction among large fund managers based on 13F institutional filings. In contrast, insider activity scores a modest 9.7 out of 25, with 14 insider transactions recorded over the past 90 days according to SEC Form 4 filings. These transactions were evenly split between 7 purchases and 7 sales, suggesting no directional consensus among company executives and directors. Dark pool activity scores 8.5 out of 25, pointing to below-average off-exchange institutional interest at current price levels. Congressional trading activity registers 7.6 out of 25, reflecting limited legislative interest in ABT shares during the observed period. The divergence between maximum institutional conviction and subdued insider activity creates a mixed signal for investors monitoring smart money flows.
Abbott Laboratories Earnings Outlook
Abbott Laboratories has delivered consistent earnings performance across recent quarters, per company earnings reports. In the most recently reported quarter, Abbott posted earnings per share of $1.31, surpassing the consensus analyst estimate of $1.28 by $0.03. The prior quarter saw EPS of $1.15 against an estimate of $1.14, representing a $0.01 positive surprise. The preceding quarter matched expectations precisely, with actual EPS of $1.50 aligning with the $1.50 consensus estimate. This pattern of meeting or modestly exceeding expectations reflects disciplined operational execution and conservative guidance practices. The upcoming quarter carries an analyst consensus estimate of $1.15 per share, with results expected on April 15, 2026. Abbott's earnings trajectory demonstrates stable profitability, though the beat magnitudes have been narrow, ranging from zero to approximately 2.3%. Analysts will be monitoring diagnostics segment trends and medical device growth as key drivers for forward earnings momentum.
Wall Street Analyst Ratings for ABT
Wall Street consensus on Abbott Laboratories remains decidedly bullish, with recent analyst actions uniformly favoring buy-equivalent ratings per SID consensus data. On August 25, 2026, TD Cowen maintained its Buy rating on ABT, reaffirming conviction in the company's growth trajectory. Wolfe Research issued the most notable action on August 13, upgrading ABT to Outperform from Peer Perform, signaling a shift in relative positioning within the healthcare coverage universe. UBS maintained its Buy rating on July 28, while both TD Cowen and RBC Capital reiterated Buy and Outperform ratings respectively on July 17 following earnings results, according to Wall Street analyst reports. The absence of any Hold, Underperform, or Sell ratings among the five most recent actions underscores broad institutional analyst confidence in Abbott's fundamentals. The Wolfe Research upgrade is particularly significant as it represents the only directional change among recent coverage updates, suggesting improving sentiment following the company's consistent earnings execution.
